Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Myelodysplastic syndromes (MDS) have a major impact on quality of life (QoL). We performed a post hoc analysis of two multicenter trials of azacitidine-based disease-modifying therapy for patients with MDS and low blast count acute myeloid leukemia (AML), to identify factors associated with QoL. 231 patients were included (median age 70 years). At baseline, higher initial hemoglobin, but not neutrophil or platelet count, was associated with better global QoL and physical function (p 

Original publication

DOI

10.1080/10428194.2021.2012664

Type

Journal article

Journal

Leuk Lymphoma

Publication Date

17/12/2021

Pages

1 - 8

Keywords

Myelodysplastic syndrome, acute myeloid leukemia, azacitidine, hemoglobin, quality of life, red cell transfusion